No regulatory body Health Canada, the FDA, the EMA, the TGA, or any equivalent has approved either component peptide, or the blend formulation, as a drug for human or veterinary use
However, he noted there may be short-term risks
Throughout the podcast Gary deftly brushes off numerous studies that contradict the CIM and continuously moves the goalposts by saying that the studies were too short, or they werent done well, but he never provides an example of how they should have been done or what was wrong with them (other than funding source, though ironically, he didnt criticize his own studies for funding source)
Research Use Only Notice For Research Use Only
Conclusion: GLP-1 Drugs Are Rewiring the Consumer Economy The Ozempic effect is not just about weight loss